Details for Patent: 11,059,829
✉ Email this page to a colleague
Which drugs does patent 11,059,829 protect, and when does it expire?
Patent 11,059,829 protects CALQUENCE and is included in one NDA.
This patent has eighty-two patent family members in twenty-nine countries.
Summary for Patent: 11,059,829
| Title: | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate |
| Abstract: | In some embodiments, the invention relates to crystalline solid forms, including hydrates, polymorphs, and salt forms, of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention relates to amorphous solid forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention also relates to pharmaceutical compositions containing the solid forms, and methods for treating conditions or disorders by administering to a subject a pharmaceutical composition that includes the forms, including pharmaceutical compositions and methods for overcoming the effects of acid reducing agents. |
| Inventor(s): | Fritz Blatter, Tim Ingallinera, Tjeerd Barf, Edwin Aret, Cecile Krejsa, Jerry Evarts |
| Assignee: | Acerta Pharma BV |
| Application Number: | US16/863,033 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,059,829 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 11,059,829
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | CALQUENCE | acalabrutinib maleate | TABLET;ORAL | 216387-001 | Aug 3, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA WHO ARE INELIGIBLE FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB | ⤷ Start Trial | ||
| Astrazeneca | CALQUENCE | acalabrutinib maleate | TABLET;ORAL | 216387-001 | Aug 3, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | ⤷ Start Trial | ||
| Astrazeneca | CALQUENCE | acalabrutinib maleate | TABLET;ORAL | 216387-001 | Aug 3, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB | ⤷ Start Trial | ||
| Astrazeneca | CALQUENCE | acalabrutinib maleate | TABLET;ORAL | 216387-001 | Aug 3, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,059,829
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2016286548 | ⤷ Start Trial | |||
| Australia | 2020277123 | ⤷ Start Trial | |||
| Australia | 2022291635 | ⤷ Start Trial | |||
| Canada | 2991096 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
